257 related articles for article (PubMed ID: 15755593)
1. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain.
Oster P; Lennon D; O'Hallahan J; Mulholland K; Reid S; Martin D
Vaccine; 2005 Mar; 23(17-18):2191-6. PubMed ID: 15755593
[TBL] [Abstract][Full Text] [Related]
2. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.
Wong SH; Lennon DR; Jackson CM; Stewart JM; Reid S; Ypma E; O'Hallahan JM; Oster P; Mulholland K; Martin DR
Pediatr Infect Dis J; 2009 May; 28(5):385-90. PubMed ID: 19384263
[TBL] [Abstract][Full Text] [Related]
4. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.
Oster P; O'Hallahan J; Aaberge I; Tilman S; Ypma E; Martin D
Vaccine; 2007 Apr; 25(16):3075-9. PubMed ID: 17289223
[TBL] [Abstract][Full Text] [Related]
6. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.
Thornton V; Lennon D; Rasanathan K; O'Hallahan J; Oster P; Stewart J; Tilman S; Aaberge I; Feiring B; Nokleby H; Rosenqvist E; White K; Reid S; Mulholland K; Wakefield MJ; Martin D
Vaccine; 2006 Feb; 24(9):1395-400. PubMed ID: 16242221
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.
Hosking J; Rasanathan K; Mow FC; Jackson C; Martin D; O'Hallahan J; Oster P; Ypma E; Reid S; Aaberge I; Crengle S; Stewart J; Lennon D
Clin Vaccine Immunol; 2007 Nov; 14(11):1393-9. PubMed ID: 17898183
[TBL] [Abstract][Full Text] [Related]
9. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers.
Jackson C; Lennon D; Wong S; Yan J; Stewart J; Reid S; Oster P; Ypma E; Martin D
Arch Dis Child; 2011 Aug; 96(8):744-51. PubMed ID: 21596727
[TBL] [Abstract][Full Text] [Related]
10. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
[TBL] [Abstract][Full Text] [Related]
11. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
Holst J; Feiring B; Naess LM; Norheim G; Kristiansen P; Høiby EA; Bryn K; Oster P; Costantino P; Taha MK; Alonso JM; Caugant DA; Wedege E; Aaberge IS; Rappuoli R; Rosenqvist E
Vaccine; 2005 Mar; 23(17-18):2202-5. PubMed ID: 15755595
[TBL] [Abstract][Full Text] [Related]
12. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease.
O'Hallahan J; Lennon D; Oster P; Lane R; Reid S; Mulholland K; Stewart J; Penney L; Percival T; Martin D
Vaccine; 2005 Mar; 23(17-18):2197-201. PubMed ID: 15755594
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
Arnold R; Galloway Y; McNicholas A; O'Hallahan J
Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
[TBL] [Abstract][Full Text] [Related]
14. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic.
Sexton K; Lennon D; Oster P; Crengle S; Martin D; Mulholland K; Percival T; Reid S; Stewart J; O'Hallahan J
N Z Med J; 2004 Aug; 117(1200):U1015. PubMed ID: 15475985
[TBL] [Abstract][Full Text] [Related]
15. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S
Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040
[TBL] [Abstract][Full Text] [Related]
16. Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.
Wedege E; Bolstad K; Aase A; Herstad TK; McCallum L; Rosenqvist E; Oster P; Martin D
Clin Vaccine Immunol; 2007 Jul; 14(7):830-8. PubMed ID: 17494638
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy.
Ameratunga S; Macmillan A; Stewart J; Scott D; Mulholland K; Crengle S;
Vaccine; 2005 Mar; 23(17-18):2231-4. PubMed ID: 15755602
[TBL] [Abstract][Full Text] [Related]
18. MeNZB vaccine and epidemic control: when do you stop vaccinating?
Loring BJ; Turner N; Petousis-Harris H
Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
[TBL] [Abstract][Full Text] [Related]
19. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.
Kelly C; Arnold R; Galloway Y; O'Hallahan J
Am J Epidemiol; 2007 Oct; 166(7):817-23. PubMed ID: 17615088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
